Healthcare - Biotechnology - NASDAQ - US
$ 1.0
0 %
$ 1.55 M
Market Cap
-0.16
P/E
CASH FLOW STATEMENT
-21.2 M
OPERATING CASH FLOW
-207 K
INVESTING CASH FLOW
24 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Kiromic BioPharma, Inc.
| Net Income | -20.9 M |
| Depreciation & Amortization | 2.22 M |
| Capital Expenditures | -207 K |
| Stock-Based Compensation | 141 K |
| Change in Working Capital | -3.21 M |
| Others | 2.4 M |
| Free Cash Flow | -21.4 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (20.9) | (34.7) | (25.6) | (19.2) | (3.7) | (3.8) |
| Depreciation & Amortization | 2.2 | 1.7 | 0.5 | 0.2 | 87.5 K | 80.9 K |
| Deferred Income Tax | 0 | 0 | 0 | 22.2 K | 0 | 0 |
| Stock Based Compensation | 0.1 | 1.2 | 3.8 | 13.2 | 0.5 | 0.6 |
| Other Operating Activities | 0.6 | 3.7 | 0.3 | 200 | 20.5 K | 0.6 |
| Change in Working Capital | (3.2) | 4.4 | 0.7 | (0.4) | 0.2 | 0.3 |
| Cash From Operations | (21.2) | (23.7) | (20.3) | (6.1) | (2.9) | (2.2) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | (0.2) | (4.9) | (1.9) | (1.5) | (0.3) | (0.1) |
| Other Items | 0 | 15 K | 84 K | 0 | 0 | 0 |
| Cash From Investing Activities | (0.2) | (4.9) | (1.8) | (1.5) | (0.3) | (0.1) |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 23.4 | 4.1 | 92.2 K | 0.5 | 0.2 | 0.7 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (0.1) | (0.2) | (2.8) | 3.0 | 4.5 | 0.9 |
| Cash From Financing Activities | 24.0 | 3.9 | 37.3 | 15.8 | 4.8 | 1.6 |
| CHANGE IN CASH | ||||||
| Net Change In Cash | 2.6 | (24.7) | 15.2 | 8.2 | 1.5 | (0.7) |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (21.4) | (28.6) | (22.2) | (7.6) | (3.2) | (2.3) |